Gene therapy for malignant glioma with the herpes simplex virus thymidine kinase / ganciclovir ( HSV -tk / GCV ) system is already in the stage of clinical trials, but still needs major improvement to achieve greater clinical efficacy. The aim of this study was to determine whether combining HSV -tk / GCV gene therapy with temozolomide ( TMZ ), an alkylating drug clinically proven to be efficient in recurrent high -grade gliomas, would result in enhanced antitumor effect in malignant glioma in culture and in vivo. Human U87MG glioblastoma ( GBM ) cells with or without expression of HSV -tk were treated with different concentrations of GCV, TMZ, or both drugs. Cell viability was accessed by an automated microplate assay ( MTT ). The isobologram method and the combination index ( CI ) method of Chou -Talalay were used to measure the interactions between the two drugs when applied simultaneously. U87 -tk and control U87 cells ( 5Â10 6 each ) were implanted in the flanks of nude mice, and animals were treated with GCV or TMZ or with both drugs. All tumors were measured and weighed at specified time points. IC 50 for GCV was 511 M in control U87 cells and 14.3 M in U87 -tk cells, resulting in 35.7 -fold increase of toxicity in the HSV -tk -expressing cells. TMZ had an IC 50 of 20.2 mM in control cells and 2.35 mM in U87 -tk cells, resulting in 8.6 -fold increase in sensitivity of the HSV -tkexpressing cells. TMZ and HSV -tk / GCV actions were synergistic ( CI < 1 ) in both control and U87 -tk cells with higher synergism in U87 -tk cells at high effect levels. Tumors expressing HSV -tk and treated with TMZ and GCV were significantly smaller than those treated by TMZ, but not by GCV. There was also a significant difference between the weight of HSV -tk expressing versus control tumors treated with TMZ, with GCV, or with both drugs. These data demonstrate synergism between HSV -tk / GCV and TMZ and higher sensitivity against TMZ in HSV -tk -expressing GBM cells. The potential importance for clinical studies combining both local tumor gene therapy and systemic chemotherapy should be explored further. Cancer Gene Therapy ( 2001 ) 8, 662 -668
P rimary brain tumors of glial origin ( gliomas ) are the most common neoplasms of the central nervous system in the adult population. 1 Gliomas do not metastasize systemically, but are exceptionally migratory and invade the surrounding brain tissue very early in their natural course. 2, 3 These tumors are graded according to a few defined histologic features, such as presence of mitosis, polymorphic nuclei, and abundant neoplastic vasculature. 4 High -grade gliomas (WHO grades III and IV ) are aggressive neoplasms with an uniformly fatal course despite modern multimodal treatment strategies including surgical resection, irradiation, and chemotherapy. 5 Gene therapy represents an attempt to improve the poor prognosis of patients with high -grade gliomas. The most often used paradigm for gene therapy of these patients is the virus -mediated transfer of the herpes simplex virus type 1 thymidine kinase gene (HSV-tk ) into tumor cells followed by systemic administration of ganciclovir ( GCV ). 6 -10 It is not necessary to achieve transduction of most tumor cells, as there is a bystander effect responsible for the killing of nontransduced cells surrounding transgene -expressing cells. 7, 11 However, the advancement of HSV-tk /GCV gene therapy for brain tumors through the stage of animal models into clinical trials has not succeeded in eliminating major efficacy -limiting factors and demonstrating significant increase of survival rates in controlled studies. 10, 12 Temozolomide ( TMZ; 8 -carbamoyl -3-methylimidazo [ 5,1-d] -1,2,3,5 -tetrazin -4 -(3H )-one ) is an oral alkylating agent that has shown promising activity in clinical trials against some malignant tumors. 13, 14 TMZ activity is attributed to the formation of a reactive methyldiazonium cation and methylation of O( 6 )-guanine in DNA. Features of TMZ attractive for use in central nervous system tumors include excellent oral bioavailability and good penetration of the blood -brain barrier. 15, 16 Further, TMZ has relatively low complications and is well tolerated in high oral doses ( > 200 mg / m 2 ). Clinical trials of TMZ in high -grade glioma ( WHO grade III anaplastic astrocytoma, AA, and WHO grade IV glioblastoma multiforme, GBM ) have reported responses in up to 50% of cases. 16 -18 In an attempt to improve the HSV-tk /GCV gene therapy paradigm, this study investigated the efficacy and possible synergism of the combination between HSV-tk /GCV and TMZ. Both treatments are clinically safe and well tolerated and have demonstrate activity against human gliomas in clinical trials. Interactions between HSV-tk /GCV and TMZ were investigated in cell culture and in an animal model of human malignant glioma.
MATERIALS AND METHODS

Cell culture experiments
The U87MG ( U87 ) human malignant glioma cell line was obtained from ATCC (Manassas, VA ), grown as monolayer culture in DMEM (Sigma, Deisenhofen, Germany ) supplemented with 10% fetal calf serum (FCS, Sigma) and 1% penicillin -streptomycin (Sigma ), and maintained in an atmosphere of 5% CO 2 at 378C. The recombinant cDNA encoding HSV-tk was placed under the control of the Moloney murine leukemia virus long terminal repeat ( LTR ) promoter in the plasmid pTLKRNL -1 ( a kind gift from Dr. X. O. Breakefield, Massachusetts General Hospital, Boston, MA ) 19 and was used for transfection and G418 -mediated selection of cell clones stably expressing HSV-tk. After screening with 10 M GCV, the U87 -tk clone with the highest demonstrated toxicity was used for all further experiments. A mock -transfected U87 clone was used as control.
Tumor cells in the logarithmic phase of growth were trypsinized, counted by trypan-blue exclusion in a hemocytometer, and plated at a density of 4Â10 3 cells per well in 96 -well microtiter plates. After an incubation period of 24 hours, medium was supplemented with different concentrations of GCV or TMZ, respectively. GCV was used in concentrations of 0, 2.5, 5, 10, 20, and 40 mM in U87 control cells, and 0, 0.25, 0.5, 1, 2, and 4 M in U87 -tk cells. TMZ was applied in concentrations of 0, 0.2, 0.4, 0.8, 1.6, and 3.2 mM in both U87 and U87 -tk cells. Four days later, the medium in each well was replaced by 0.5 mg /mL MTT ( Sigma ) in DMEM. After 3 hours incubation at 378C, MTT was removed, and the intracellular formazan crystals were solubilized in 100 l isopropanol /0.1 N HCl according to manufacturer's instructions. Absorbance was read at 570 and 630 nm on a microplate reader ( ELÂ800, Biotek Instruments, Heidelberg, Germany ).
Determining drug interactions
To calculate combined drug effects, the combination index ( CI )-isobologram method of Chou-Talalay was used. 20, 21 This method involves plotting of dose -effect curves for each agent and combinations thereof in multiply diluted concentrations by using the median-effect equation and plot 22, 23 and the CI equation and plot. 21, 22, 24 The method takes into account not only the potency of each drug and their combination (D m values ), but also the shape of their dose -effect curves ( m values ), and determines then how much the experimental effect differs from the effect expected with additivity. CI =1, < 1, and > 1 indicates additive effect, synergism, and antagonism, respectively. The CI values can be determined at different effect and different dose levels, and the isobolograms can be automatically generated by using a computer software. 25 
Animal experiments
Thirty adult male nude mice (nu /nu, 20 g body weight, Charles River, Krefeld, Germany ) were used for this study. Animal care and experimental procedures were performed in accordance with the local guidelines for animal experiments. Briefly, 5Â10 5 tumor cells in a volume of 100 l DMEM without FCS and antibiotics were injected subcutaneously in the flanks of the experimental animals. Each animal hosted on contralateral sites in parallel a U87 control *Dose -effect relationship parameters were calculated on the median -effect equation using a computer software. 25 D m signifies the potency represented by the median -effect dose, which in this case is the concentration ( M ) that inhibits the cell growth by 50%. m signifies the shape of the dose -effect curve, where m = 1, m > 1, and m < 1 indicates hyperbolic, sigmoidal, and negative sigmoidal, respectively. r signifies the conformity of data of the method employed, which in this case is the linear correlation coefficient of the median -effect plot.
yCI was calculated on the multiple drug effect equation derived by Chou and Talalay, 21, 22 using computer software. 25 CI < 1, CI = 1, and CI > 1 indicate synergism, additive effect, and antagonism, respectively. D m and m values for single drugs and their combinations were used for CI calculation using the equation 2 , where D x is the dose ( concentration ) for x% inhibition.zDRI ( dose -reduction index ) is measured by comparing the doses required to reach a given degree of inhibition when the drug was used alone and in combination with another drug.
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RAINOV, FELS, DRÖ GE, ET AL: TEMOZOLOMIDE AND HSV -tk / GCV COMBINATION IN MALIGNANT GLIOMA tumor and a U87 -tk tumor. Tumors were allowed to grow for 7 days, then animals were randomly assigned to one of three groups and injected intraperitoneally either with GCV ( 30 mg /kg twice daily), with TMZ ( 100 mg /kg, once daily), or both agents at the indicated doses. Injections were continued for 14 days. Tumor extensions were measured daily in two planes, and size was calculated by multiplying the two diameters. Animals were killed 24 days after tumor implantation, and all tumors were excised, weighed, formalin -fixed, and paraffin-embedded. Paraffin sections (6 m ) were cut and stained with hematoxylin and eosin for light microscopic evaluation. The Origin 5.0 software ( Microcal, Northampton, MA ) and independent Student's t test were used to calculate statistical significance of differences in tumor size and weight.
RESULTS
Cell culture
The sensitivity of U87 and U87 -tk cells to different concentrations of GCV and/ or TMZ was evaluated to characterize the activity and the interactions of these drugs as single agents or in combination. HSV-tk -expressing cells were 35.7 times more sensitive to GCV than U87 control cells (Table 1) . IC 50 for GCV was 14.3 M for U87 -tk cells and 511 M for control U87 cells. HSV-tk -expressing cells were 8.6 times more sensitive to TMZ compared to U87 controls, and had an IC 50 of 2.35 versus 20.2 mM in controls ( Table 1 ). These results demonstrate that sensitivity to GCV was amplified in HSV-tk -transfected cells, and that the difference was statistically significant ( Student's t test, P < .01). Surprisingly, sensitivity to TMZ was also increased in U87 -tk cells compared to U87 control cells ( P< .05 ), although TMZ is not a known substrate of HSV-tk. U87 -tk cells were treated with combinations of GCV and TMZ in different concentrations such that their IC 50 ratio ( M ) was 1:800, approximating their median-effect dose ratio so that the contribution of each drug in the combination was about equal (Table 1 ). In both U87 and U87 -tk cells, the CI for determining synergism was below 1 for all f a (affected cell fraction ) values, indicating synergism at all effect levels for IC 50 to IC 90 with somewhat more synergism (i.e., lower CI values ) for U87 -tk cells than for U87 cells ( Table 1 ). The dose reduction index (DRI ) showed favorable dose reduction for both drugs as a result of synergism (Table  1 ) . Synergistic effects are also demonstrated for GCV and TMZ in both U87 -tk and U87 glioma cells as shown in Figure 1 .
Animal experiments
The size of U87 control tumors in nude mice treated with TMZ, GCV, with both drugs, or with saline ( control ) was not significantly different ( Fig 2A ) . Tumors expressing HSV-tk and treated with TMZ and GCV were significantly smaller than those treated by TMZ, but not by GCV ( Fig 2B ) . As determined by tumor weight, the burden of HSV-tkexpressing tumors was significantly smaller than that of U87 control tumors after treatment with the single agents TMZ or GCV or with their combination (Fig 3 ) . There also were statistically significant differences between the weights of untreated U87 -tk tumors and U87 -tk tumors treated with TMZ or GCV or with both agents. All tumors in all treatment groups had similar light microscopic appearance: intense vascularization, dense cellularity, high number of mitotic figures, and multiple necrotic areas ( data not shown ).
DISCUSSION
The present study was performed to investigate the feasibility of a novel therapeutic concept involving a combination of suicide gene therapy and chemotherapy for the treatment of malignant glioma. It provided evidence that HSV-tk / GCV gene therapy and TMZ chemotherapy can be combined for enhanced cytotoxicity of malignant glioma. In culture, the cytotoxic interactions of TMZ and GCV were synergistic in both U87 -tk and U87 glioma cells at all effect levels, with a greater synergism for U87 -tk than for U87 cells, as determined by the CI -isobologram method of Chou-Talalay 21,22,25 (see Table 1 and Figure 1 ). U87 -tk cells were significantly more sensitive against treatment with the single agent TMZ than control mock -transfected U87 cells. In nude mice, subcutaneous HSV-tk expressing tumors were significantly smaller upon combined TMZ / GCV treatment compared with the corresponding U87 controls ( Fig 2 ) . There also were significant differences between the weights of HSV-tk -expressing versus nonexpressing control tumors treated with TMZ, with GCV, or with both drugs (Fig 3 ) .
Mechanisms of action and synergy between HSV -tk / GCV and TMZ
Future studies have to elucidate possible mechanisms by which synergy between suicide gene therapy systems and conventional chemotherapeutic agents is mediated. A number of reported findings in the literature could be employed for explaining HSV-tk /GCV and TMZ synergy in malignant glioma.
GCV is a guanosine analogue and binds to the same active site of HSV-tk as thymidine, although with a considerably higher K m (0.2 vs 100 M). 26 Therefore, thymidine outcompetes nucleoside analogues such as GCV for phosphorylation by HSV-tk, and GCV phosphorylation is the rate -limiting step in GCV-mediated toxicity to HSV-tkexpressing tumor cells. 27 GCV resistance may arise intracellularly from altered binding activity of DNA polymerase for GCV-triphosphate. 28 TMZ breakdown in the cell generates an electrophilic reactive methyldiazonium ion intermediate that reacts with more nucleophilic sites in the major groove of DNA. 29 This results in methyl adducts at the O( 6 )-guanine of DNA, which can be repaired by O( 6) -alkylguanine-DNA alkyltransferase ( ATase ). 30 TMZ toxicity in human tumor cell lines correlates with the level of expression of ATase. O( 6 ) - Values are expressed as mean and standard deviation ( bars ). There are statistically significant differences between the mean size of tumors treated with TMZ or with GCV ( P < .01 ), with TMZ or with both drugs ( P < .01 ), and with GCV or with NaCl ( control ) ( P < .01 ). No significant differences were calculated between the mean size of tumors treated with TMZ or with NaCl ( P > .05 ) or with GCV and with both drugs ( P > .05 ). All P values were calculated using Student's t test.
Cancer Gene Therapy, Vol 8, No 9, 2001 RAINOV, FELS, DRÖ GE, ET AL: TEMOZOLOMIDE AND HSV -tk / GCV COMBINATION IN MALIGNANT GLIOMA Benzylguanine irreversibly inactivates the ATase and thus increases tumor cell sensitivity to alkylating agents such as carmustine, lomustine, procarbazine, and TMZ. 30 On the other hand, tumor cell resistance against TMZ can result from overexpression of O( 6 )-methylguanine -DNA methyltransferase (MGMT ), a DNA repair protein that removes alkyl adducts from DNA. Human brain tumors have a significant fraction of cells with high levels of MGMT. O( 6 )-benzylguanine also reduces significantly MGMT levels in human and murine tumor cells. 31 One potential mechanism for the synergy between HSV-tk and TMZ may be the GCV metabolite -mediated inhibition of the repair of TMZ -induced DNA cross -links. There are analogous findings described in the literature, e.g., the synergy between classical alkylating agents such as cisplatin or cyclophosphamide and nucleoside analogues such as ara -C or fludarabine, 18, 32 resulting from nucleoside analogues inhibiting the repair of DNA cross -links formed by alkylating agents. Furthermore, it was shown that GCVtriphosphate inhibits DNA polymerase , an enzyme involved in repair of DNA cross -links. 33 Measurement of synergy between HSV -tk / GCV and TMZ An important issue in interpreting the results of this study concerns the methods that were used for assessment of synergy. The CI -isobologram method of ChouTalalay 21, 22, 25 is the only method employing actually derived equations from the mass action principle offering quantitative analyses of drug interactions by first defining the additive effect. 21 -23 Rigorous examination by this method of data from cell culture allowed us to clearly identify a synergy between the two drugs at all effect levels. This was additionally proven in an animal study utilizing exactly the same cell clones and drugs. Assessment of synergy in vivo is recognized as difficult, and therefore it was important to perform quantitative drug combination studies in a malignant glioma cell culture study before starting animal experiments.
In our animal study, we used drug doses that are somewhat higher than actually used in humans. The standard dose for TMZ in patients previously untreated by chemotherapy is 200 mg /m 2 on 5 days followed by 3 weeks drug -free period, compared to 100 mg /kg body weight (300 mg /m 2 ) in mice ( 2 mg total daily dose per animal ) on 14 consecutive days. TMZ given to humans in single daily doses of 150 mg /m 2 has a rapid absorption with maximum concentrations achieved on average in 1 hour, and also a rapid elimination with a half -life averaging 1.8 hours. The maximum systemic concentration of TMZ in patients varies between 9.5 and 16 g /mL plasma, 34 which is well above the IC 50 concentration for TMZ in our cell culture experiments, but probably below the systemic TMZ concentration in the animal experiments.
GCV is administered in humans at a total daily dose of 10 mg /kg ( 400 mg /m 2 ) divided in two equal doses every 12 hours compared to a total daily dose of 60 mg /kg body weight ( 180 mg / m 2 ) in mice (1.2 mg total daily dose per animal ). GCV treatment in humans generates peak plasma concentrations of 45 M, although the intracellular concentration is presumably below this value. 28 The calculated IC 50 for HSV-tk -expressing cells in culture is lower that the above value. Therefore, based on the above pharmacological Figure 3 . Weight of tumors removed on day 24 after implantation. Treatment groups: ( 1 ) nontreated control U87 -tk tumors and ( 2 ) control U87 tumors ( no significant difference, P > .05 ); ( 3 ) U87 -tk tumors and ( 4 ) U87 tumors treated with TMZ ( P < .01 ); ( 5 ) U87 -tk tumors and ( 6 ) U87 tumors treated with GCV ( P < .01 ); ( 7 ) U87 -tk tumors and ( 8 ) U87 tumors treated with TMZ / GCV ( P < .01 ). There are statistically significant differences between the weights of U87 -tk control tumors ( 1 ) and U87 -tk tumors treated with TMZ ( 3 ) ( P < .01 ), with GCV ( 5 ) ( P < .01 ), or with both ( 7 ) ( P < .01 ). There are no statistically significant differences between the weights of U87 control tumors ( 2 ) and U87 tumors treated with TMZ ( 4 ) ( P > .05 ), with GCV ( 6 ) ( P > .05 ), or with both ( 8 ) ( P > .05 ). All P values were calculated using Student's t test.
data, the feasibility of a clinical study combining both HSVtk / GCV gene therapy and oral TMZ at doses equal or slightly higher than the currently recommended may be predicted. Besides the synergistic cytotoxic effect, another advantage of combining HSV-tk /GCV gene therapy with TMZ would be the fact that this combination of drugs may reduce toxicity toward the host as indicated by the DRI ( Table 1) and may decrease the impact of possible acquired drug resistance of the tumor cells.
Summarizing our data, the demonstration of synergy between HSV-tk / GCV gene therapy and chemotherapy with TMZ suggests a possible enhanced therapeutic concept for future studies in human malignant glioma. Despite many still unknown variables, the present results were clearly defined in a glioma cell culture system and confirmed in animal experiments, and therefore justify further investigation. 
